Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 4/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.37 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.37 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.37 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.37 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777322 | 0.78 | DPP4 (0.46) | — | |
| SCHEMBL17926168 | 0.77 | DPP4 (0.48) | GRM5GRM1GRIA1MEN1KMT2A | |
| SCHEMBL3762472 | 0.74 | CASP6 (0.54) | MAPK1NAMPTMEN1KMT2ALMNA | |
| SCHEMBL3766563 | 0.72 | DPP4 (0.65) | — | |
| SCHEMBL29676965 | 0.71 | MAPK1 (0.64) | MAPK1NAMPT | |
| SCHEMBL5183098 | 0.71 | MAPK1 (0.64) | MAPK1NAMPT | |
| SCHEMBL16518028 | 0.71 | UCHL1 (0.49) | MAPK1NAMPTMEN1KMT2A | |
| SCHEMBL22638739 | 0.70 | ESR2 (0.52) | MAPK1 | |
| SCHEMBL12197348 | 0.69 | MAPK1 (0.46) | MAPK1NAMPT | |
| SCHEMBL14996188 | 0.69 | NPC1 (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250157-B1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | SLC34A1 298/4885MAPK1 2715/4885GRM5 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.